Bristol-Myers Squibb Co Q3 2020 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Giovanni, you've made it very clear that cardiovascular is a core franchise for the company. On Factor XIa, what do you think you have to deliver in terms of clinical profile to enable that asset to add value in what will potentially be a generic environment? And then maybe more strategically, in cardiovascular, it looks like you have at one end of the spectrum, kind of a mass market, Eliquis and Factor XIa approach, and on the other hand, a more specialized approach with MyoKardia. So I assume your strategic vision in cardiovascular spans across that. But curious if you want to be more focused in one end or the other as you consider additional BD and cardiovascular. And then a follow-up for David. How would you describe the LOE step-down for Revlimid in the coming years? And do you think The Street has that right, at least in general in terms of how it's being modeled? We obviously have imperfect information. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.